NEW YORK (GenomeWeb) – Interpace Diagnostics today said that it has regained compliance with a Nasdaq listing requirement calling for at least $2.5 million in stockholder equity.
As a result, the company's shares will remain listed on the Nasdaq Capital Market.
The firm was notified in November that it failed to meet the listing requirement and faced delisting action. On April 10, though, it received a letter from Nasdaq saying it had regained compliance.
In January, Interpace regained compliance on another listing requirement calling for a minimum $1 bid price per share. The company effected a 1-for-10 reverse stock split in December in order to meet that requirement.
In early morning trading, Interpace's shares rose about 3 percent to $2.25.